Payment overview · 2025
General Payments
$748.79
38 reported records · 12 companies
Healthcare provider profile · identity verified
Bradley David Mcfadden, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · COLUMBUS, OH · NPI 1720473549
Verified facts
What the public records show
CMS Open Payments records show Bradley David Mcfadden, D.O. received $748.79 in general payments during 2025 across 38 reported records.
ABBVIE INC. accounted for 31.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $232.67 | 31.1% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $126.28 | 16.9% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $77.81 | 10.4% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $71.93 | 9.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $71.72 | 9.6% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $42.12 | 5.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.14 | 3.9% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $26.20 | 3.5% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $21.38 | 2.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.38 | 2.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.40 | 2.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.76 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $748.79 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $113.74 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $96.03 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $89.54 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $77.18 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $77.18 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $44.95 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $42.12 | 2 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $41.32 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $37.62 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.10 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $32.86 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $32.86 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.13 | 2 | 2025 |
Source payment records
|
|||||
| CDS - Other Normalized: cds other |
Device | Boston Scientific Corporation | $30.61 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $29.14 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $29.14 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $26.20 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.80 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.40 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.76 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 101 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 119 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 103 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
119 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
103 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
101 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 357 | 99 |
| Atorvastatin Calcium | Atorvastatin Calcium | 335 | 97 |
| Losartan Potassium | Losartan Potassium | 231 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 216 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 203 | 54 |
| Lisinopril | Lisinopril | 181 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 124 | 39 |
| Jardiance | Empagliflozin | 119 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 118 | 35 |
| Omeprazole | Omeprazole | 116 | 31 |
| Ozempic | Semaglutide | 103 | 16 |
| Eliquis | Apixaban | 101 | 23 |
| Valsartan | Valsartan | 96 | 26 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 94 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 85 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 83 | 22 |
| Allopurinol | Allopurinol | 76 | 22 |
| Metformin Hcl | Metformin Hcl | 71 | 26 |
| Sertraline Hcl | Sertraline Hcl | 71 | 16 |
| Gabapentin | Gabapentin | 68 | 23 |
| Trazodone Hcl | Trazodone Hcl | 66 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 61 | 22 |
| Carvedilol | Carvedilol | 57 | 16 |
| Ezetimibe | Ezetimibe | 57 | 16 |
| Metformin Hcl Er | Metformin Hcl | 51 | 16 |
| Bupropion Xl | Bupropion Hcl | 47 | 14 |
| Furosemide | Furosemide | 46 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 45 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 15 |
| Azithromycin | Azithromycin | 42 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 40 | 12 |
| Prednisone | Prednisone | 40 | 33 |
| Synthroid | Levothyroxine Sodium | 39 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 35 |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | 11 |
| Alendronate Sodium | Alendronate Sodium | 36 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Atenolol | Atenolol | 33 | 13 |
| Valacyclovir | Valacyclovir Hcl | 33 | 15 |
| Montelukast Sodium | Montelukast Sodium | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 24 |
| Simvastatin | Simvastatin | 29 | 12 |
| Meloxicam | Meloxicam | 28 | 16 |
| Methylprednisolone | Methylprednisolone | 28 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 24 | 11 |
| Finasteride | Finasteride | 24 | suppressed |
| Ketoconazole | Ketoconazole | 23 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 17 |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Tenivac | Tetanus-Diphtheria Toxoids/Pf | 18 | 18 |
| Cephalexin | Cephalexin | 17 | 16 |
| Lorazepam | Lorazepam | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 16 |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | 12 |
| Calcitriol | Calcitriol | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $748.79 · 38 records | ABBVIE INC. | AIRSUPRA, AREXVY, BodyGuardian, CAPVAXIVE, CDS - Other, ELIQUIS, EVENITY, GARDASIL 9, JARDIANCE, NEFFY, NURTEC ODT, OPSUMIT, OTEZLA, Ozempic, PROLIA, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, UPTRAVI, VRAYLAR, Veozah, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error